Сартаны в лечении артериальной гипертензии: фокус на телмисартан и азилсартан
- Авторы: Закиев В.Д.1, Котовская Ю.В.1, Ткачева О.Н.1
-
Учреждения:
- ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России
- Выпуск: Том 95, № 9 (2023)
- Страницы: 810-817
- Раздел: Обзоры
- URL: https://journals.rcsi.science/0040-3660/article/view/254698
- DOI: https://doi.org/10.26442/00403660.2023.09.202423
- ID: 254698
Цитировать
Полный текст
Аннотация
Активность ренин-ангиотензин-альдостероновой системы является одним из основных патогенетических механизмов, лежащих в основе сердечно-сосудистых заболеваний на всех этапах сердечно-сосудистого континуума. В данной статье рассматривается роль телмисартана и азилсартана как самых сильных сартанов по своему антигипертензивному эффекту в современной кардиологической практике. Азилсартан и в особенности телмисартан обладают выраженной органопротекцией и превосходят другие антигипертензивные средства в отношении снижения артериального давления. Однако влияние азилсартана на жесткие конечные точки не изучалось, в то время как эффективность телмисартана оценивалась во множестве клинических исследований, включая 3 крупных рандомизированных клинических исследования с участием нескольких тысяч пациентов. В статье также представлены расчеты, свидетельствующие об экономической эффективности телмисартана по сравнению с азилсартаном.
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Вадим Дмитриевич Закиев
ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России
Email: zakiev739@gmail.com
ORCID iD: 0000-0003-4027-3727
младший научный сотрудник лаборатории клинической фармакологии и фармакотерапии, ОСП «Российский геронтологический научно-клинический центр»
Россия, МоскваЮлия Викторовна Котовская
ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России
Email: zakiev739@gmail.com
ORCID iD: 0000-0002-1628-5093
доктор медицинских наук, профессор, заместитель директора по научной работе ОСП «Российский геронтологический научно-клинический центр»
Россия, МоскваОльга Николаевна Ткачева
ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России
Автор, ответственный за переписку.
Email: zakiev739@gmail.com
ORCID iD: 0000-0002-4193-688X
член-корреспондент РАН, доктор медицинских наук, профессор, заведующая кафедрой болезней старения, директор Обособленного структурного подразделения «Российский геронтологический научно-клинический центр»
Россия, МоскваСписок литературы
- Mehta JK, Kaur G, Buttar HS, et al. Role of the renin-angiotensin system in the pathophysiology of coronary heart disease and heart failure: Diagnostic biomarkers and therapy with drugs and natural products. Front Physiol. 2023;14:1034170. doi: 10.3389/fphys.2023.1034170
- Bhardwaj G. How the antihypertensive losartan was discovered. Expert Opin Drug Discov. 2006;1(6):609-18. doi: 10.1517/17460441.1.6.609
- Государственный реестр лекарственных средств. Режим доступа: https://grls.rosminzdrav.ru/Default.aspx. Ссылка активна на 15.07.2023 [State register of medicines. Available at: https://grls.rosminzdrav.ru/Default.aspx. Accessed: 15.07.2023 (in Russian)].
- Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-35. doi: 10.1016/s0140-6736(03)14739-3
- Baguet JP, Robitail S, Boyer L, et al. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs. 2005;5(2):131-40. doi: 10.2165/00129784-200505020-00007
- Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi: 10.1136/bmj.b1665
- Wei J, Galaviz KI, Kowalski AJ, et al. Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications: A Systematic Review and Network Meta-analysis. JAMA Netw Open. 2020;3(2):e1921618. doi: 10.1001/jamanetworkopen.2019.21618
- Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41-6. doi: 10.1016/s0002-9343(03)00158-x
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi: 10.1093/eurheartj/ehy339
- Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? J Am Coll Cardiol. 2018;71(13):1474-82. doi: 10.1016/j.jacc.2018.01.058
- Wu VC, Lin YF, Teng NC, et al. Angiotensin II Receptor Blocker Associated With Less Outcome Risk in Patients With Acute Kidney Disease. Front Pharmacol. 2022;13:714658. doi: 10.3389/fphar.2022.714658
- Yang SY, Huang TM, Lai TS, et al. Nsarf Study Group. Angiotensin II Receptor Blockers but Not Angiotensin-Converting Enzyme Inhibitors Are Associated With a Reduced Risk of Acute Kidney Injury After Major Surgery. Front Pharmacol. 2021;12:662301. doi: 10.3389/fphar.2021.662301
- Zaiken K, Cheng JW. Azilsartan medoxomil: a new Angiotensin receptor blocker. Clin Ther. 2011;33(11):1577-89. doi: 10.1016/j.clinthera.2011.10.007
- Ojima M, Igata H, Tanaka M, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther. 2011;336(3):801-8. doi: 10.1124/jpet.110.176636
- Westerink J, Visseren F. Cardiovasc Pharmacological and nonpharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol. 2011;10(13):18. doi: 10.1186/1475-2840-10-13
- Ayza MA, Zewdie KA, Tesfaye BA, et al. Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity. Diabetes Metab Syndr Obes. 2020;13:3627-35. doi: 10.2147/DMSO.S265399
- Benndorf RA, Rudolph T, Appel D, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism. 2006;55(9):1159-64. doi: 10.1016/j.metabol.2006.04.013
- Usui I, Fujisaka S, Yamazaki K, et al. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract. 2007;77(2):210-4. doi: 10.1016/j.diabres.2006.11.014
- Kiyici S, Guclu M, Budak F, et al. Even Short-Term Telmisartan Treatment Ameliorated Insulin Resistance But Had No Influence on Serum Adiponectin and Tumor Necrosis Factor-Alpha Levels in Hypertensive Patients with Metabolic Syndrome. Metab Syndr Relat Disord. 2019;17(3):167-72. doi: 10.1089/met.2018.0129
- Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens. 2007;25(4):841-8. doi: 10.1097/HJH.0b013e3280287a83
- Suksomboon N, Poolsup N, Prasit T. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J Clin Pharm Ther. 2012;37(3):319-27. doi: 10.1111/j.1365-2710.2011.01295.x
- Takagi H, Umemoto T; All-Literature Investigation of Cardiovascular Evidence Group. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. J Am Soc Hypertens. 2014;8(8):578-92. doi: 10.1016/j.jash.2014.05.006
- Parati G, Schumacher H, Bilo G, Mancia G. Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database. J Hypertens. 2010;28(11):2177-83. doi: 10.1097/HJH.0b013e32833e1150
- Parati G, Schumacher H. Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan-amlodipine monotherapy and combination. Hypertens Res. 2014;37(3):187-93. doi: 10.1038/hr.2013.145
- Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther. 2008;325(2):349-56. doi: 10.1124/jpet.107.130294
- Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013;65:809-48. doi: 10.1124/pr.112.007278
- Williams B, Gosse P, Lowe L, et al. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipri l using ambulatory blood pressure monitoring (PRISMA I). J Hypertens. 2006;24:193-200. doi: 10.1097/01.hjh.0000194364.11516.ab
- Lacourcière Y, Neutel JM, Davidai G, et al. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens. 2006;19:104-12. doi: 10.1016/j.amjhyper.2005.10.001
- Gosse P, Neutel JM, Schumacher H, et al. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit. 2007;12:141-7. doi: 10.1097/MBP.0b013e3280b10bbd
- Gosse P, Schumacher H. Effect of telmisartan vs. ramipril on 'dipping' status and blood pressure variability: pooled analysis of the PRISMA studies. Hypertens Res. 2014;37(2):151-7. doi: 10.1038/hr.2013.121
- Neutel JM, Frishman WH, Oparil S, et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther. 1999;6(3):161-6. doi: 10.1097/00045391-199905000-00007
- Takagi H, Niwa M, Mizuno Y, et al. A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure. Hypertens Res. 2013;36(11):959-66. doi: 10.1038/hr.2013.78
- Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens (Greenwich). 2003;5(1):58-63. doi: 10.1111/j.1524-6175.2003.01612.x
- Takagi H, Niwa M, Mizuno Y, et al.; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction. Hypertens Res. 2013;36(7):627-33. doi: 10.1038/hr.2012.233
- Wang JG, Zhang M, Feng YQ, et al. Is the newest angiotensin-receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta-analysis. J Clin Hypertens (Greenwich). 2021;23(5):901-14. doi: 10.1111/jch.14227
- Kumari K, Toppo MS, Majhi L, Kumar A. Blood pressure-lowering effect of telmisartan compared to losartan among mild to moderate essential hypertensive adult subjects: A meta-analysis. J Family Med Prim Care. 2022;11(10):6227-35. doi: 10.4103/jfmpc.jfmpc_787_22
- Neldam S, Edwards C; ATHOS Study Group. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol. 2006;15(3):151-60. doi: 10.1111/j.1076-7460.2006.05219.x
- Lacourcière Y, Lenis J, Orchard R, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit. 1998;3(5):295-302.
- Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375(9718):895-905. doi: 10.1016/S0140-6736(10)60308-X
- Chang TI, Reboussin DM, Chertow GM, et al. SPRINT Research Group*. Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension. 2017;70(4):751-8. doi: 10.1161/HYPERTENSIONAHA.117.09788
- de Havenon A, Petersen N, Wolcott Z, et al. Effect of dihydropyridine calcium channel blockers on blood pressure variability in the SPRINT trial: a treatment effects approach. J Hypertens. 2022;40(3):462-9. doi: 10.1097/HJH.0000000000003033
- Cohen MC, Rohtla KM, Lavery CE, et al. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol. 1997;79(11):1512-6. doi: 10.1016/s0002-9149(97)00181-1
- Elliott WJ. Circadian variation in the timing of stroke onset: a meta-analysis. Stroke. 1998;29(5):992-6. doi: 10.1161/01.str.29.5.992
- Bönner G, Bakris GL, Sica D, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013;27(8):479-86. doi: 10.1038/jhh.2013.6
- Gitt AK, Bramlage P, Potthoff SA, et al.; EARLY Registry Group. Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. BMC Cardiovasc Disord. 2016;16:56. doi: 10.1186/s12872-016-0222-6
- Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011;13(7):467-72. doi: 10.1111/j.1751-7176.2011.00482.x
- Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res. 2012;35(5):552-8. doi: 10.1038/hr.2012.8
- Wu J, Du X, Lv Q, et al. A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension. Medicine (Baltimore). 2020;99(32):e21465. doi: 10.1097/MD.0000000000021465
- White WB, Cuadra RH, Lloyd E, et al. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016;34(4):788-97. doi: 10.1097/HJH.0000000000000839
- Ferdinand KC, Bakris GL, Cushman WC, et al. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. Am J Cardiol. 2018;122(9):1496-505. doi: 10.1016/j.amjcard.2018.07.022
- Baker WL, White WB. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother. 2011;45(12):1506-15. doi: 10.1345/aph.1Q468
- Takagi H, Mizuno Y, Niwa M, et al. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertens Res. 2014;37(5):432-7. doi: 10.1038/hr.2013.142
- Nakajima T, Oh A, Saita S, et al. Comparative Effectiveness of Angiotensin II Receptor Blockers in Patients With Hypertension in Japan – Systematic Review and Network Meta-Analysis. Circ Rep. 2020;2(10):576-86. doi: 10.1253/circrep.CR-20-0076
- Zhao D, Liu H, Dong P. Antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension: a meta-analysis. Ir J Med Sci. 2019;188(2):481-8. doi: 10.1007/s11845-018-1859-1
- Dargad RR, Parekh JD, Dargad RR, Kukrety S. Azilsartan: Novel Angiotensin Receptor Blocker. J Assoc Physicians India. 2016;64(3):96-8.
- Garg M, Manik G, Singhal A, et al. Efficacy and Safety of Azilsartan Medoxomil and Telmisartan in Hypertensive Patients: A Randomized, Assessor-Blinded Study. Saudi J Med Med Sci. 2020;8(2):87-94. doi: 10.4103/sjmms.sjmms_19_19
- Sinha S, Chary S, Reddy Bandi M, et al. Azilsartan Study In Indian Adult Patients Of Essential Hypertension Investigators Azilehi Group. Evaluation of the Efficacy and Safety of Azilsartan in Adult Patients with Essential Hypertension: A Randomized, Phase-III Clinical Study in India. J Assoc Physicians India. 2021;69(2):35-9.
- Reddy S, Rohini M, Prasanna, et al. Comparative study of efficacy and safety of azilsartan with telmisartan in hypertensive patients. International Journal of Contemporary Medical Research. 2018;5(5):E51-4. doi: 10.21276/ijcmr.2018.5.5.40
- Meher BR, Mohanty RR, Sahoo JP, et al. Comparative Study of the Effects of Azilsartan and Telmisartan on Insulin Resistance and Metabolic Biomarkers in Essential Hypertension Associated With Type 2 Diabetes Mellitus. Cureus. 2022;14(2):e22301. doi: 10.7759/cureus.22301
- Bhosle DS, Khan S, Mubeen MF, Quazi Z. Comparative study to evaluate efficacy and safety of azilsartan and telmisartan in patients with grade I-II essential hypertension. Int J Basic Clin Pharmacol. 2003;7(1):184-90. doi: 10.18203/2319-2003.ijbcp20175697
- Cowan BR, Young AA, Anderson C, et al. ONTARGET Investigators. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). Am J Cardiol. 2009;104(11):1484-9. doi: 10.1016/j.amjcard.2009.07.018
- Petrovic I, Petrovic D, Vukovic N, et al. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res. 2005;33 Suppl. 1:39A-49A. doi: 10.1177/14732300050330S106
- Galzerano D, Tammaro P, del Viscovo L, et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens. 2005;18(12 Pt. 1):1563-9. doi: 10.1016/j.amjhyper.2005.06.011
- Yusuf S, Teo KK, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-83. doi: 10.1016/S0140-6736(08)61242-8
- Asmar R, Gosse P, Topouchian J, et al. Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. J Renin Angiotensin Aldosterone Syst. 2003;3:176-80. doi: 10.3317/jraas.2002.038
- Takagi H, Yamamoto H, Iwata K, et al.; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials. Int J Cardiol. 2013;167(4):1443-9. doi: 10.1016/j.ijcard.2012.04.058
- Makino H, Haneda M, Babazono T, et al.; INNOVATION Study Group. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res. 2008;31(4):657-64. doi: 10.1291/hypres.31.657
- Liu CH, Sung PS, Li YR, et al. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study. PLoS Med. 2021;18(7):e1003707. doi: 10.1371/journal.pmed.1003707
- Kusuyama T, Ogata H, Takeshita H, et al. Effects of azilsartan compared to other angiotensin receptor blockers on left ventricular hypertrophy and the sympathetic nervous system in hemodialysis patients. Ther Apher Dial. 2014;18(5):398-403. doi: 10.1111/1744-9987.12168
- Петросов С.Л., Фомин В.В. Опыт применения азилсартана медоксомила (Эдарби) у пациентов с артериальной гипертензией в амбулаторной практике. Фарматека. 2015;9:51-5 [Petrosov SL, Fomin VV. Opyt primeneniia azilsartana medoksomila (Edarbi) u patsientov s arterial'noi gipertenziei v ambulatornoi praktike. Pharmateca. 2015;9:51-5 (in Russian)].
- Невзорова В.А., Петричко Т.А., Чазова И.Е., Жернакова Ю.В. от имени участников исследования. Состояние функции почек у больных артериальной гипертонией в сочетании с ожирением и метаболическими нарушениями на фоне терапии азилсартана медоксомилом. Терапевтический архив. 2021;93(12):1510-5 [Nevzorova VA, Petrichko TA, Chazova IE, Zhernakova JuV, on behalf of the research participants. The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(12):1510-5 (in Russian)]. doi: 10.26442/00403660.2021.12.201270
- Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59. doi: 10.1056/NEJMoa0801317
- Yusuf S, Diener H, Sacco R, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225-37. doi: 10.1056/NEJMoa0804593
- Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53. doi: 10.1056/NEJM200001203420301
- Ageev FT, Smirnova MD. Clinical Efficacy and Tolerability of Antihypertensive Therapy with Single Pill Combinations of Telmisartan in Patients with Arterial Hypertension in Clinical Practice According to the ON TIME Observational Study. Rational Pharmacother Cardiol. 2022;18(6):638-47. doi: 10.20996/1819-6446-2022-12-01
- Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-67. doi: 10.1016/S0140-6736(15)01225-8
- Чазова И.Е., Жернакова Ю.В., Звартау Н.Э., и др. Результаты российского, многоцентрового, открытого, проспективного исследования эффективности и безопасности препаратов Телмиста® и Телмиста® H у пациентов с артериальной гипертензией 1 и 2 степени. Системные гипертензии. 2022;19(2):17-26 [Chazova IE, Zhernakova YuV, Zvartau NE, et al. Results of a Russian multicenter open prospective study of the efficacy and safety of Telmista® and Telmista® H in patients with arterial hypertension 1 and 2 degrees. Systemic Hypertension. 2022;19(2):17-26 (in Russian)]. doi: 10.38109/2075-082X-2022-2-17-26